It has been suggested that angiotensin II may promote endothelial oxidative stress by XO activation; conversely, in patients with coronary disease, losartan therapy reduces endothelium-bound XO activity, likely contributing to improved endothelial function [36]. The gene discussed is XDH; the disease is coronary artery disorder.